CRISPR Therapeutics AG (CRSP)

Name: CRISPR Therapeutics AG (CRSP) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001674416 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, CRISPR Therapeutics AG reported revenue of $3.51M. Revenue fell 90.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $13.39M.

Key ratios (year ended 2025-12-31)

n/m

Operating margin

n/m

Net margin

-30.3%

Return on year-end equity

-90.6%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-19

Headquarters locality: Zug · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$13.39M	$3.51M	$37.31M	$371.21M	$1.20M	$914.96M	$719.0K	$289.59M	$3.12M	$41.00M	$5.16M
R&D Expense	$278.15M	$284.81M	$310.24M	$387.33M	$461.64M	$340.57M	$221.38M	$179.36M	$113.77M	$69.80M	$42.24M
Operating Income	-$534.34M	-$664.57M	-$466.57M	-$222.54M	-$673.16M	$373.53M	-$354.44M	$46.74M	-$158.94M	-$64.65M	-$68.13M
Depreciation & Amortization	$18.69M	$19.48M	$19.26M	$19.84M	$24.17M	$17.95M	$9.18M	$4.72M	$3.52M	$3.02M	$925.0K
EBITDA	-$515.65M	-$645.09M	-$447.31M	-$202.70M	-$648.99M	$391.48M	-$345.25M	$51.47M	-$155.42M	-$61.62M	-$67.20M
Net Income	-$451.14M	-$581.60M	-$366.25M	-$153.61M	-$650.17M	$377.66M	-$348.87M	$66.86M	-$164.98M	-$68.36M	-$23.18M
EPS (Diluted)	n/a	-$6.47	-$4.34	-$1.94	-$8.36	$4.70	-$5.29	$1.17	-$3.44	-$1.71	n/a
Total Assets	$2.65B	$2.27B	$2.24B	$2.23B	$2.24B	$2.75B	$1.83B	$1.07B	$489.02M	$271.35M	$344.96M
Total Liabilities	$904.22M	$343.43M	$309.95M	$346.77M	$367.58M	$352.42M	$163.73M	$127.33M	$96.82M	$83.51M	$112.12M
Shareholders' Equity	$1.75B	$1.92B	$1.93B	$1.88B	$1.88B	$2.40B	$1.66B	$939.42M	$392.19M	$187.83M	$232.85M
Cash & Equivalents	$291.34M	$347.56M	$298.26M	$389.48M	$211.88M	$923.03M	$1.17B	$943.77M	$456.65M	$239.76M	$315.52M
Operating Cash Flow	-$369.58M	-$345.01M	-$142.77M	-$260.38M	-$495.74M	$538.97M	-$238.37M	$56.68M	-$96.24M	-$70.09M	-$52.86M
Capital Expenditures	$1.74M	$914.0K	$1.90M	$9.47M	$37.19M	$81.70M	$18.36M	$6.68M	$2.77M	$7.81M	$3.02M
Free Cash Flow	-$371.32M	-$345.93M	-$144.68M	-$269.85M	-$532.93M	$457.27M	-$256.72M	$49.99M	-$99.01M	-$77.91M	-$55.88M
Share Repurchases	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$57.0K	n/a	n/a
Shares Outstanding	96.66M	95.89M	85.74M	80.04M	78.51M	76.99M	73.91M	60.78M	51.85M	40.59M	39.72M
Weighted Average Diluted Shares	n/a	89.93M	84.36M	79.22M	77.75M	80.39M	65.95M	56.93M	47.96M	40.06M	n/a
EPS (Basic)	n/a	-$6.47	-$4.34	-$1.94	-$8.36	$4.97	-$5.29	$1.23	-$3.44	-$1.71	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView